Your browser doesn't support javascript.
loading
Synthesis, biological evaluation and 3D-QSAR studies of imidazolidine-2,4-dione derivatives as novel protein tyrosine phosphatase 1B inhibitors.
Wang, Mei-Yan; Jin, Yuan-Yuan; Wei, Hui-Yu; Zhang, Li-Song; Sun, Su-Xia; Chen, Xiu-Bo; Dong, Wei-Li; Xu, Wei-Ren; Cheng, Xian-Chao; Wang, Run-Ling.
Afiliación
  • Wang MY; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.
  • Jin YY; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.
  • Wei HY; Tianjin Medical University Eye Hospital, Tianjin 300384, China.
  • Zhang LS; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.
  • Sun SX; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.
  • Chen XB; Tianjin Medical University Eye Hospital, Tianjin 300384, China.
  • Dong WL; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.
  • Xu WR; Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China.
  • Cheng XC; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin 300070, China. Electronic address: chengxianchao@aliyun.com.
  • Wang RL; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin 300070, China. Electronic address: wangrunling@tijmu.edu.cn.
Eur J Med Chem ; 103: 91-104, 2015 Oct 20.
Article en En | MEDLINE | ID: mdl-26342135
Protein tyrosine phosphatase 1B (PTP1B) plays a vital role in the regulation of insulin sensitivity and dephosphorylation of the insulin receptor, so PTP1B inhibitors may be potential agents to treat type 2 diabetes. In this work, a series of novel imidazolidine-2,4-dione derivatives were designed, synthesized and assayed for their PTP1B inhibitory activities. These compounds exhibited potent activities with IC50 values at 0.57-172 µM. A 3D-QSAR study using CoMFA and CoMSIA techniques was carried out to explore structure activity relationship of these molecules. The CoMSIA model was more predictive with q(2) = 0.777, r(2) = 0.999, SEE = 0.013 and r(2)pred = 0.836, while the CoMFA model gave q(2) = 0.543, r(2) = 0.998, SEE = 0.029 and r(2)pred = 0.754. The contour maps derived from the best CoMFA and CoMSIA models combined with docking analysis provided good insights into the structural features relevant to the bioactivity, and could be used in the molecular design of novel imidazolidine-2,4-dione derivatives.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Relación Estructura-Actividad Cuantitativa / Imidazolidinas / Inhibidores Enzimáticos / Proteína Tirosina Fosfatasa no Receptora Tipo 1 Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Eur J Med Chem Año: 2015 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Relación Estructura-Actividad Cuantitativa / Imidazolidinas / Inhibidores Enzimáticos / Proteína Tirosina Fosfatasa no Receptora Tipo 1 Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Eur J Med Chem Año: 2015 Tipo del documento: Article País de afiliación: China
...